Daily Roundup

CSL.ASX ING.ASX DNL.ASX BXN.ASX AI1.ASX

CSL Ltd Provides Interim CEO Update and Revised FY26 Guidance

CSL Limited today shared an update from Interim CEO Gordon Naylor, highlighting early signs of improvement in the company's portfolio and commercial execution. However, the financial benefits of CSL's growth initiatives and transformation program are taking longer than anticipated to materialize, leading to a revision of the FY26 guidance.

CSL now expects FY26 revenue to be around $15.2 billion and NPATA (excluding restructuring costs and impairments) to be around $3.1 billion, both on a constant currency basis. The key changes are related to U.S. Immunoglobulin, Albumin in China, and other factors.

Despite the revised guidance, CSL continues to expect revenue growth in the second half of FY26 for CSL Behring, supported by underlying demand, ongoing commercial execution, and benefits from operational and transformation initiatives. The company also announced approximately $5 billion in non-cash, pre-tax impairments across FY26 and FY27, primarily related to CSL Vifor intangible assets and under-utilized property, plant, and equipment.

The global search for CSL's next CEO is progressing, and Gordon Naylor will remain on the CSL Board as a Non-executive Director following the appointment and transition of the new CEO. Additionally, Chief Commercial Officer Andy Schmeltz has decided to retire, with Diego Sacristan assuming the role effective July 1, 2026.

Inghams Group Outlines Investor Day and Trading Update

Inghams Group Ltd is hosting an Investor Day presentation on May 11, 2026, providing an overview of its strategy to stabilize the business, optimize the asset, and grow the value. The company highlights that the poultry industry remains an attractive category, but Inghams' past returns have not reflected the quality of its asset base due to operational inconsistency, capital productivity issues, and increased competitive intensity.

To address this, Inghams is shifting its focus from a volume-led to a value-led approach, aiming to maximize value per bird and drive sustainable earnings and growth. Key elements of the strategy include winning with customers through freshness, reliability, and consumer-led innovation, unlocking trapped value in operations through standardization and planning discipline, and leveraging New Zealand as a strategic market.

Inghams expects to deliver over $130 million in EBITDA uplift from operational improvements and planning discipline over the next 3 years, and the company is confident in its ability to deliver sustainable growth and improved returns.

Dyno Nobel Reports Strong 1H26 Results and Reaffirms FY26 Guidance

Dyno Nobel Limited (DNL) reported strong 1H26 results, highlighting the resilience of its explosives business. The company's underlying EBIT grew by 28% year-on-year, driven by customer wins in core and growth markets, as well as strong manufacturing performance capitalizing on tightening markets.

DNL is on track to deliver its FY28 EBIT ambition of $600 million, with a FY26 exit run rate of 65%-75%. The company also announced the signing of a binding agreement for the divestment of its Phosphate Hill business and reaffirmed its FY26 Explosives EBIT guidance of $460 million to $500 million.

Safety remains a top priority for Dyno Nobel, with improvements in process safety and a reduction in injury severity. The company continues to see positive momentum across all its business units, with customer wins and growth opportunities in key markets such as Ghana, Brazil, and Peru.

Bioxyne Expands LATAM Footprint with First Supply Agreement in Costa Rica

Bioxyne Ltd, through its subsidiary Breathe Life Sciences (BLS), has executed an expanded supply agreement with Remidose LATAM SRL to include the supply of three Dr Watson® cannabis flower SKUs to Costa Rica. This agreement represents the first international supply of medicinal cannabis flower into Costa Rica's regulated market.

The initial shipment is expected to exceed $500,000, and the company expects repeat orders, subject to market conditions and regulatory approvals. This expansion establishes early Dr Watson® brand positioning and creates a regulatory and distribution foothold intended to support broader expansion across LATAM as the markets continue to open.

Adisyn Subsidiary 2D Radar Signs MOU to Develop Radar Absorbing Drone Components

Adisyn's subsidiary, 2D Radar Absorbers Ltd, has signed an MOU with Raval, one of Israel's largest plastics groups, to co-develop graphene-enhanced injection-moulded parts for radar absorption in drones and unmanned aerial vehicles (UAVs). The collaboration combines 2D Radar's graphene-based stealth materials platform with Raval's industrial-scale, automotive-grade production capabilities, providing Adisyn with a direct route from development to commercial manufacturing.

This uniquely integrated stealth materials platform positions Adisyn to engage with defence and UAV customers, as time-to-field is increasingly mission-critical for these customers.